公开(公告)号：EP2869852A4

公开(公告)日：2016-04-20

申请号：EP13817579

申请日：2013-07-09

Applicant: METHEOR THERAPEUTICS CORP ,  SLEDZIEWSKI ANDREW Z ,  DEVOS THEODORE ,  KOLE RYSZARD

Inventor： SLEDZIEWSKI ANDREW Z ,  DEVOS THEODORE ,  KOLE RYSZARD

IPC: A61K48/00 ,  C12N15/113

CPC classification number: C12N15/1137 ,  C12N2310/13 ,  C12N2310/33 ,  C12N2310/3341 ,  C12N2310/531 ,  C12Y201/01037

公开(公告)号：EP2869852A2

公开(公告)日：2015-05-13

申请号：EP13817579.9

申请日：2013-07-09

Applicant: Metheor Therapeutics Corporation ,  Sledziewski, Andrew Z. ,  Devos, Theodore ,  Kole, Ryszard

Inventor： SLEDZIEWSKI, Andrew, Z. ,  DEVOS, Theodore ,  KOLE, Ryszard

IPC: A61K48/00 ,  A61K38/55

CPC classification number: C12N15/1137 ,  C12N2310/13 ,  C12N2310/33 ,  C12N2310/3341 ,  C12N2310/531 ,  C12Y201/01037

Abstract: Modified oligonucleotides comprising CpG sites, wherein the cytosine is replaced by cytosine analogs are provided as well as methods of making the oligonucleotides and their use in inhibiting DNA Methyltransferase, inhibiting or reversing methylation of genes and in treating cancer, tumorigenesis and hyper-proliferative disorders.

公开(公告)号：EP3382018A1

公开(公告)日：2018-10-03

申请号：EP16868667.3

申请日：2016-11-25

Applicant: National University Corporation Gunma University

Inventor： HATADA, Izuho ,  MORITA, Sumiyo ,  HORII, Takuro

IPC: C12N15/09 ,  C07K16/18 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N9/10

CPC classification number: C12N15/907 ,  C07K16/18 ,  C12N1/00 ,  C12N5/10 ,  C12N9/10 ,  C12N15/09 ,  C12N15/111 ,  C12N2310/20 ,  C12Y201/01037

Abstract: A DNA methylation editing kit comprises: (1) a fusion protein of inactivated CRISPR-associated endonuclease Cas9 (dCas9) having no nuclease activity and a tag peptide array in which plural tag peptides are linked by linkers, or an RNA or DNA coding therefor; (2) a fusion protein(s) of a tag peptide-binding portion and a methylase or demethylase, or an RNA(s) or DNA(s) coding therefor; and (3) a guide RNA(s) (gRNA(s)) comprising a sequence complementary to a DNA sequence within 1 kb of a desired site of methylation or demethylation, or a DNA(s) expressing the gRNA(s).

公开(公告)号：EP3209783A1

公开(公告)日：2017-08-30

申请号：EP15794644.3

申请日：2015-10-23

Applicant: Ospedale San Raffaele S.r.l. ,  Fondazione Telethon

Inventor： NALDINI, Luigi ,  LOMBARDO, Angelo Leone ,  AMABILE, Angelo ,  MIGLIARA, Alessandro

IPC: C12N15/85 ,  A61K48/00 ,  A61K38/45 ,  C12N9/10

CPC classification number: C12N9/1007 ,  A61K35/12 ,  A61K38/1709 ,  A61K38/45 ,  A61K48/005 ,  C07K14/4703 ,  C07K2319/80 ,  C12N2740/16043 ,  C12Y201/01037 ,  C12Y201/01043

Abstract: A product comprising two or more artificial transcription repressors (ATRs), or polynucleotides encoding therefor, selected from groups (a), (b), (c) or (d): (a) an ATR comprising a DNA-binding domain operably linked to a KRAB domain or homologue thereof; (b) an ATR comprising a DNA-binding domain operably linked to a DNMT3A, DNMT3B or DNMT1 domain or homologue thereof; (c) an ATR comprising a DNA-binding domain operably linked to a DNMT3L domain or homologue thereof; and (d) an ATR comprising a DNA-binding domain operably linked to a SETDB1 domain or homologue thereof, wherein at least two of the ATRs are selected from different groups (a), (b), (c) or (d).

Abstract translation: 包含选自组（a），（b），（c）或（d）的两种或更多种人工转录阻遏物（ATR）或其编码多核苷酸的产物：（a）包含可操作连接的DNA结合结构域的ATR 到KRAB结构域或其同源物; （b）包含可操作地连接于DNMT3A，DNMT3B或DNMT1结构域或其同源物的DNA结合结构域的ATR; （c）包含可操作地连接至DNMT3L结构域或其同源物的DNA结合结构域的ATR; （d）包含可操作地连接至SETDB1结构域或其同源物的DNA结合结构域的ATR，其中至少两个ATR选自不同的组（a），（b），（c）或（d）。

公开(公告)号：EP3180348A1

公开(公告)日：2017-06-21

申请号：EP15829322.5

申请日：2015-08-08

Applicant: Baylor College of Medicine

Inventor： RAU, Rachel ,  GOODELL, Margaret A.

IPC: C07H19/16 ,  C12Q1/48

CPC classification number: C12Q1/6886 ,  A61K31/00 ,  A61K31/519 ,  A61K31/52 ,  C07H19/16 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Y201/01037

Abstract: The present disclosure relates to methods of treating AML, associated with DNMT3A mutations by administering one or more DOT1L inhibitors or related pharmaceutical compositions to subjects in need thereof.

Abstract translation: 本公开涉及通过向有需要的受试者施用一种或多种DOTIL抑制剂或相关药物组合物来治疗与DNMT3A突变相关的AML的方法。

公开(公告)号：EP2829599A1

公开(公告)日：2015-01-28

申请号：EP13764964.6

申请日：2013-02-21

Applicant: Institute Of Microbiology, Chinese Academy Of Sciences

Inventor： WEN, Tingyi ,  ZHANG, Guoqiang ,  DENG, Aihua

IPC: C12N1/21 ,  C12N15/24 ,  C12N1/20 ,  C12R1/19 ,  C12R1/01 ,  C12R1/07 ,  C12R1/085

CPC classification number: C12N15/70 ,  C12N1/20 ,  C12N9/1007 ,  C12N15/74 ,  C12N15/75 ,  C12R1/19 ,  C12Y201/01037

Abstract: The present invention discloses a method for introducing an exogenous DNA by overcoming the restriction modification barrier of the target bacterium. The method provided in the present invention comprises the steps of 1) co-expressing all DNA-methyltransferase-encoding genes in the genome of the target bacterium in E. coli in which the restriction modification system thereof has been deleted to obtain a recombinant bacterium A; 2) introducing an exogenous DNA molecule into the recombinant bacterium A for in vivo modification so as to obtain a methylation-modified exogenous DNA molecule; 3) introducing the methylation-modified exogenous DNA molecule into the target bacterium. The experiments of the invention have demonstrated that the invention has a high transformation efficiency compared to prior methods for enabling genetic manipulation by overcoming the restriction modification barrier of the bacterium.

Abstract translation: 本发明公开了通过克服目标细菌的限制性修饰屏障来引入外源DNA的方法。 本发明提供的方法包括以下步骤：1）在其缺失限制性修饰系统的大肠杆菌中共表达靶细菌基因组中的所有DNA-甲基转移酶编码基因，获得重组细菌A ; 2）将外源DNA分子引入用于体内修饰的重组细菌A中，以获得甲基化修饰的外源DNA分子; 3）将甲基化修饰的外源DNA分子引入目标细菌。 本发明的实验已经证明，与通过克服细菌的限制性修饰屏障进行遗传操作的现有方法相比，本发明具有高的转化效率。

公开(公告)号：KR1020150054415A

公开(公告)日：2015-05-20

申请号：KR1020130136827

申请日：2013-11-12

Applicant: 서울대학교산학협력단

Inventor： 김재범 ,  김아영

IPC: C12Q1/68 ,  G01N33/53 ,  C12N5/07

CPC classification number: G01N33/5044 ,  C12Y201/01037 ,  G01N2333/46 ,  G01N2333/91017

Abstract: 본발명은 DNMT1을이용한비만또는대사성질환치료제스크리닝방법에관한것으로서, 세포를배양하는단계; 상기세포에후보물질을처리하는단계; 상기세포에서아디포넥틴프로모터의메틸화를측정하는단계; 및상기아디포넥틴프로모터의메틸화가대조군에비해감소된것을확인하는단계를포함하는것을특징으로하는비만또는대사성질환치료제스크리닝방법을제공한다. 또한, DNMT1 활성억제제를포함하는비만또는대사성질환치료제를제공한다.

Abstract translation: 本发明涉及用DNMT1筛选肥胖或代谢紊乱的治疗剂的方法。 该方法包括以下步骤：培养细胞; 在细胞上加工候选物质; 测量细胞中脂联素启动子的甲基化; 检查脂联素启动子的甲基化是否低于对照组。

公开(公告)号：JP2018528968A

公开(公告)日：2018-10-04

申请号：JP2018514851

申请日：2016-09-16

Applicant: ユニバーシティ オブ マサチューセッツ

Inventor： グリーン,マイケル,アール. ,  ファン,ミンカン ,  コートニウク,ウォルター

IPC: C12N15/113 ,  C12Q1/00 ,  C12Q1/48 ,  C12Q1/6813 ,  C12Q1/6851 ,  A61K31/7068 ,  A61K31/548 ,  A61K31/7105 ,  A61K31/713 ,  A61K39/395 ,  A61P25/00 ,  A61P43/00 ,  G01N33/15 ,  G01N33/50 ,  A61K45/00

CPC classification number: A61K48/005 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/549 ,  A61K31/706 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/713 ,  A61K35/30 ,  A61K38/45 ,  A61K38/53 ,  A61K39/3955 ,  A61K48/0016 ,  A61P15/02 ,  A61P25/14 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12Q1/6883 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Y201/01037 ,  C12Y201/01043 ,  C12Y603/02019

Abstract: 本開示は、サイレンシングされたFMR1遺伝子を再活性化するための方法および組成物に関する。いくつかの側面において、本開示によって記載される方法は、FMR1不活性化に関連する異常(例えば脆弱X症候群)を処置することにとって有用である。

公开(公告)号：JP6140804B2

公开(公告)日：2017-05-31

申请号：JP2015502066

申请日：2013-02-21

Applicant: 中国科学院微生物研究所

Inventor： ウェン ティンイ ,  チャン グォチン ,  デン アイファ

IPC: C12N1/21 ,  C12N9/10 ,  C12N15/09

CPC classification number: C12N15/70 ,  C12N1/20 ,  C12N15/74 ,  C12N15/75 ,  C12N9/1007 ,  C12R1/19 ,  C12Y201/01037

公开(公告)号：KR101363412B1

公开(公告)日：2014-03-19

申请号：KR1020120111460

申请日：2012-10-08

Applicant: 서울대학교산학협력단

Inventor： 신찬석 ,  박준현 ,  황동규

IPC: A01H5/00 ,  C12N15/113 ,  C12N15/82

CPC classification number: C12N15/8218 ,  C07K14/415 ,  C12N9/1007 ,  C12N15/113 ,  C12N2310/141 ,  C12Y201/01037

Abstract: The present invention provides a method for regulating DRM (domain rearranged methyltransferase) protein activity in a plant comprising: base sequences represented by sequence number 1 or 2; a microRNA-396 molecule which consists of base sequences complementary to the above base sequences and which is isolated from Capsicum annuum; a vector containing the microRNA-396; and a step for regulating the expression of the microRNA-396 molecule by transfecting a plant cell with the recombinant vector. On the basis of a method for controlling all phenomena related to the florescence, seed development, and epigenetic phenomenon of the plant based on the fact that the aspect of regulating the DRM methyltransferase, which is highly involved in plant epigenetics, by the microRNA-396 from the Capsicum annuum is conserved in the Solanaceae including tomatoes revealed by the present invention, the DRM methyltransferase can be applied to agricultural biotechnology for improving traits of food crops, forage crops, floriculture crops, horticultural crops, and energy crops and be available for various medical applications like differentiation of cancer cells and neural cells, which are mainly involbed in epigenetic information, thereby being able to be very useful in many different fields.

Abstract translation: 本发明提供了一种用于调控植物中DRM（域重排甲基转移酶）蛋白活性的方法，包括：由序列号1或2表示的碱基序列; 由与上述碱基序列互补的碱基序列组成并从辣椒分离的微小RNA-396分子; 含有microRNA-396的载体; 以及通过用重组载体转染植物细胞来调节微小RNA-396分子的表达的步骤。 基于通过微小RNA-396调控高度参与植物表观遗传学的DRM甲基转移酶的方面，控制与植物的荧光，种子发育和表观遗传现象相关的所有现象的方法的基础上， 辣椒科中包括本发明披露的番茄科，其保藏的DRM甲基转移酶可用于农业生物技术，用于改善粮食作物，牧草作物，花卉作物，园艺作物和能源作物的性状，并可用于各种 医学应用如癌细胞和神经细胞的分化，其主要在表观遗传信息中被牵制，从而能够在许多不同领域中非常有用。